The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | NeoFox: Foxy-5, a WNT5A mimicking peptide, in stage II/III colon cancer
Ramon Salazar, MD, PhD, Institut Català D’Oncologia, Barcelona, Spain, discusses the Phase II NeoFox study (2018-003074-27) of Foxy-5, a WNT5A mimicking peptide, in stage II/III colon cancer. In the trial, Foxy-5 significantly reduced venous and perineural invasion and increased TNM downstaging. Foxy-5 additionally was well tolerated and had an acceptable safety profile. These findings suggest Foxy-5 may enhance patient outcomes and warrant further prospective validation. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
